Trial of Controversial Alzheimer’s Drug Halted After Disappointing ...
2024年11月26日 · The company announced on Monday that the drug, simufilam, did not significantly reduce cognitive decline in people with mild to moderate Alzheimer’s disease in …
End looms for Cassava's simufilam in Alzheimer's disease
2024年11月26日 · In the 804-subject study, simufilam-treated patients saw a 2.8-point change from baseline after 52 weeks on the ADAS-Cog12 cognition scale, while the placebo group …
Alzheimer Agent Simufilam Fails Phase 3, Lamotrigine Trial in DLB ...
3 天之前 · Welcome to this special edition of Neurology News Network. I'm Marco Meglio. New topline data from the phase 3 ReThink-ALZ study (NCT04994483) showed that treatment with …
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary …
2024年11月25日 · Simufilam, an investigational oral, small molecule drug candidate that targets the filamin A protein, is under evaluation for the potential treatment of Alzheimer's disease. …
A Controversial Alzheimer's Drug Has Gone Down in Flames
2024年11月26日 · Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by allegations of poorly done and fraudulent …
Simufilam found safe in review of ongoing Alzheimer's clinical trials
2024年9月26日 · After completing a third review of interim safety data, an independent safety monitoring board has recommended the continuation — without modifications — of two …
Topline results of Phase 3 studies of simufilam for Alzheimer's...
2024年2月8日 · Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s …
Simufilam aids cognition in 47% of Alzheimer's patients in Phase 2...
2023年3月14日 · Nearly half of some 200 mild-to-moderate Alzheimer’s patients treated with oral simufilam for one year showed gains in cognitive tests.
No Decline in Cognition Scores in Patients with Mild Alzheimer's ...
AUSTIN, Texas, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today reported top-line results of a two-year clinical safety …
Scientists Investigating Alzheimer’s Drug Faulted in Leaked Report
2023年10月14日 · In August 2021, two scientists filed a citizen’s petition with the Food and Drug Administration in which they described “grave concerns about the quality and integrity” of the …